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The SARS-CoV-2 virus has infected over 21 million
people globally and its disease, COVID-19, is responsi-
ble for more than 770,000 deaths.1 Since discovery,
researchers and clinicians across the world have raced
to understand how COVID-19 spreads, who is most at
risk, and how best to diagnose and treat those infected.
Others have been developing vaccines at an unprece-
dented pace. Meanwhile, policymakers have focused
on the difficult balancing act of preserving crashing
economies, enabling children to attend school, and peo-
ple to work while simultaneously trying to control the
spread of COVID-19.
A great deal has been learnt about who is at higher risk
from COVID-19. It is now recognised that those from
minority ethnic or socioeconomically deprived back-
grounds and those with specific long-term conditions
(LTCs), such as diabetes, are likely to have worse
COVID-19 outcomes.2 However, despite the rising global
prevalence of multimorbidity (the presence of 2 LTCs),
research on the implications of COVID-19 for those with
multimorbidity is sparse. Subsequently, there is no public
health advice tailored to this growing proportion of the
world’s population.
Multimorbidity is strongly associated with mortality in
those with COVID-19.3 Deaths from COVID-19 are a
source of a substantial number of years of life lost, even
after taking multimorbidity into account.4 This means that
those with multiple LTCs who died from COVID-19 still
had many years of life ahead prior to infection. Thus, to
prevent this premature mortality, it is imperative to inves-
tigate the risks posed by COVID-19 for those with multi-
morbidity and generate evidence that can determine how
best to stratify the risk for people with specific numbers and
types of LTCs alongside their sociodemographic character-
istics. Such data is crucial to empower clinicians and pol-
icymakers to give optimal advice to those with differing
patterns and extents of multimorbidity and to reduce the
impact of COVID-19 that is mediated through
multimorbidity.
Some early studies have started the process of develop-
ing COVID-19 risk stratification for those with multimor-
bidity. For example, emerging evidence indicates that both
multimorbidity (especially cardiometabolic multimorbid-
ity) and polypharmacy (often a proxy for multimorbidity)
are associated with a higher risk of COVID-19 infection.5
In addition, when factors known to be associated with
poorer COVID-19 outcomes (e.g. non-white ethnicity,
socioeconomic deprivation, and obesity) are combined
with multimorbidity, the association with COVID-19 is
even starker.5
While much public health advice provides substantial
information about the increased COVID-19 risks posed
by individual LTCs such as cancer or cardiovascular dis-
ease there is a glaring absence of information about multi-
morbidity. Public health resources, such as those from the
Centers for Disease Control and Prevention (USA), do not
highlight the higher risks of COVID-19 for people with
multimorbidity, despite the evidence highlighted here.
While there are many patient representative organisations
for specific conditions such as Asthma UK, the American
Heart Association, and the European Cancer Patient Coali-
tion, organisations that focus on chronic illness in general
are rare and fewer, if any, target multimorbidity. Such
organisations are a vital and trusted source of information
and support for patients, carers, and the public and provide
ample advice and information about the risks of COVID-19
to individuals with specific LTCs. In contrast, those with
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multimorbidity remain largely forgotten and disadvantaged
through the scarcity of organisations that advocate specif-
ically for those with multiple LTCs and via the absence of
information tailored to their complex needs.
This dearth of information and support also means
employers are less aware of the risks faced by their employ-
ees with multimorbidity. Organisations are therefore less
likely to make workplace adaptations that they might do for
those affected with single LTCs. Equally, people living
with multimorbidity may be unaware of the additional
COVID-19 risks associated with having a combination of
multiple LTCs as opposed to just one. These issues are
particularly important for those already identified as being
at higher risk, for example, those of non-white ethnicity.
Here the gaps in research, policy, and practice relating to
multimorbidity and COVID-19 are laid bare. Although
these gaps potentially represent shortcomings of research
funders and the wider public health and health practitioner
community, they also represent opportunities for us all to
do more to protect those most vulnerable to COVID-19.
Consequently, as part of this appeal for urgent action on
multimorbidity and to mitigate the devastating impact of
COVID-19, we make the following recommendations:
1. Research funders must call for COVID-19 research
with a multimorbidity focus.
2. Public health and policy advice that defines and
classifies who is at high risk of COVID-19 needs
to highlight the increased risks for those living with
multimorbidity.
3. Occupational health advice must include and com-
municate the additional risks and precautions for
individuals with multimorbidity, especially for
those already known to be at heightened risk.
4. Clinical guidelines need to incorporate the
increased risk posed by multimorbidity and specific
LTC combinations.
The Journal of Comorbidity recognises the importance
of understanding more about multimorbidity and COVID-
19, and now has a special call for papers which can be
found here:
https://journals.sagepub.com/page/cob/call-for-papers/spe
cial-topics/multimorbidity-or-comorbidity-and-covid-19.
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